Back to Search
KRESHNIK ZEJNULLAHU, MD
MD
Internal Medicine Physician
NPI: 1326465444IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
A140878(CA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
Class of 2014
Research & Publications (5)
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
PMID 18980991·Clin Cancer Res·2008
8-other
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
PMID 18594010·Clin Cancer Res·2008
8-other
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
PMID 18089823·Cancer Res·2007
7-preclinical
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
PMID 17463250·Science·2007
7-preclinical
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
PMID 16906227·J Clin Invest·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2700 GRANT ST STE 200
CONCORD, CA 94520 - Phone
- (925) 674-2609
Quick Facts
- NPI
- 1326465444
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 12
- Publications
- 5
Are you this provider?
Claim Your Profile